

# THERAPEUTIC AGENTS AND METHODS OF USE THEREOF FOR THE MODULATION OF ANGIOGENESIS

5

## **Related Application**

This application is a continuation-in-part of U.S. patent application Serial No. 09/972,772, filed October 5, 2001, pending; which in turn is a continuation-in-part of U.S. patent application Serial No. 09/704,251, filed November 1, 2000, pending. The  
10 entire contents of each of the aforementioned applications are hereby incorporated by reference.

## **Background of the Invention**

Angiogenesis is the fundamental process by which new blood vessels are formed  
15 and is essential to a variety of normal body activities (such as reproduction, development and wound repair). Although the process is not completely understood, it is believed to involve a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the primary cells of the capillary blood vessels. Under normal conditions, these molecules appear to maintain the microvasculature in a quiescent state  
20 (*i.e.*, one of no capillary growth) for prolonged periods which may last for as long as weeks or in some cases, decades. When necessary, however, (such as during wound repair), these same cells can undergo rapid proliferation and turnover within a 5 day period (Folkman, J. and Shing, Y., *Journal of Biological Chemistry*, 267(16): 10931-10934, and Folkman, J. and Klagsbrun, M. (1987) *Science*, 235: 442-447).

Although angiogenesis is a highly regulated process under normal conditions,  
25 many diseases (characterized as "angiogenic diseases") are driven by persistent unregulated angiogenesis. Otherwise stated, unregulated angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. For example, ocular neovascularization has been implicated as the most common cause of  
30 blindness and dominates approximately 20 eye diseases. In certain existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman, J. (1986) *Cancer Research* 46: 467-473 and Folkman, J. (1989)  
35 *Journal of the National Cancer Institute* 82: 4-6). It has been shown, for example, that tumors which enlarge to greater than 2 mm, must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the

circulation and metastasize to distant sites, such as the liver, lung or bone (Weidner, N., *et al.* (1991) *The New England Journal of Medicine* 324(1):1-8).


Fumagillin is a known compound which has been used as an antimicrobial and antiprotozoal. Its physicochemical properties and method of production are well known (U.S. Pat. No. 2,803,586 and *Proc. Nat. Acad. Sci. USA* (1962) 48:733-735). Fumagillin and certain types of Fumagillin analogs have also been reported to exhibit anti-angiogenic activity. However, the use of such inhibitors (*e.g.*, TNP-470) may be limited by their rapid metabolic degradation, erratic blood levels, and by dose-limiting central nervous system (CNS) side effects.

Accordingly, there is still a need for angiogenesis inhibitors which are more potent, less neurotoxic, more stable, and/or have longer serum half-lives.

### Summary of the Invention

The present invention provides angiogenesis inhibitor compounds which comprise a core, *e.g.*, a Fumagillin core, that is believed to inhibit methionine aminopeptidase 2 (MetAP-2), coupled to a peptide. The present invention is based, at least in part, on the discovery that coupling the MetAP-2 inhibitory core to an amino acid residue or an amino acid derivative prevents the metabolic degradation of the angiogenesis inhibitor compound to ensure a superior pharmacokinetic profile and limits CNS side effects by altering the ability of the angiogenesis inhibitor compound to cross the blood brain barrier. The present invention is also based, at least in part, on the discovery that coupling the MetAP-2 inhibitory core to a peptide comprising a site-directed sequence allows for a cell specific delivery of the angiogenesis inhibitor compound and limits the toxicity of the angiogenesis inhibitor compound.

Accordingly, the present invention provides compounds of Formula I,



In Formula I, A is a MetAP-2 inhibitory core, W is O or NR<sub>2</sub>, and R<sub>1</sub> and R<sub>2</sub> are each, independently, hydrogen or alkyl; X is alkylene or substituted alkylene, preferably linear C<sub>1</sub>-C<sub>6</sub>-alkylene; n is 0 or 1; R<sub>3</sub> and R<sub>4</sub> are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or arylalkyl or

substituted or unsubstituted heteroaryl or heteroalkyl.  $R_3$  and  $R_4$  can also, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or  $R_1$  and  $R_4$  together can form an alkylene group; Z is  $-C(O)-$ , alkylene- $C(O)-$  or alkylene; and P is a peptide comprising from 1 to about 100 amino acid residues attached at its

5 amino terminus to Z or a group  $OR_5$  or  $N(R_6)R_7$ , wherein  $R_5$ ,  $R_6$  and  $R_7$  are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl.  $R_6$  and  $R_7$  can also form, together with the nitrogen atom to which they are attached, a substituted or unsubstituted heterocyclic ring structure.

In another embodiment of the compounds of Formula I, W, X, n,  $R_1$ ,  $R_3$  and  $R_4$

10 have the meanings given above for these variables; Z is  $-O-$ ,  $-NR_8-$ , alkylene- $O-$  or alkylene- $NR_8-$ , where  $R_8$  is hydrogen or alkyl; and P is hydrogen, alkyl, preferably normal or branched  $C_1$ - $C_4$ -alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z.

In compounds of Formula I, when any of  $R_1$ - $R_8$  is an alkyl group, preferred alkyl

15 groups are substituted or unsubstituted normal, branched or cyclic  $C_1$ - $C_6$  alkyl groups. Particularly preferred alkyl groups are normal or branched  $C_1$ - $C_4$  alkyl groups. A substituted alkyl group includes at least one non-hydrogen substituent, such as an amino group, an alkylamino group or a dialkylamino group; a halogen, such as a fluoro, chloro, bromo or iodo substituent; or hydroxyl.

20 When at least one of  $R_3$  and  $R_4$  is a substituted or unsubstituted aryl or heteroaryl group, preferred groups include substituted and unsubstituted phenyl, naphthyl, indolyl, imidazolyl and pyridyl. When at least one of  $R_3$  and  $R_4$  is substituted or unsubstituted arylalkyl or heteroarylalkyl, preferred groups include substituted and unsubstituted benzyl, naphthylmethyl, indolylmethyl, imidazolylmethyl and pyridylmethyl groups.

25 Preferred substituents on aryl, heteroaryl, arylalkyl and heteroarylalkyl groups are independently selected from the group consisting of amino, alkyl-substituted amino, halogens, such as fluoro, chloro, bromo and iodo; hydroxyl groups and alkyl groups, preferably normal or branched  $C_1$ - $C_6$ -alkyl groups, most preferably methyl groups. X is preferably linear  $C_1$ - $C_6$ -alkylene, more preferably  $C_1$ - $C_4$ -alkylene and most

30 preferably methylene or ethylene. When Z is alkylene- $C(O)-$ , alkylene- $O-$  or alkylene- $NR_8$ , the alkylene group is preferably linear  $C_1$ - $C_6$ -alkylene, more preferably  $C_1$ - $C_4$ -alkylene and most preferably methylene or ethylene.


$R_6$  and  $R_7$ , in addition to alkyl, substituted alkyl or hydrogen, can each also independently be a substituted or unsubstituted azacycloalkyl group or a substituted or

35 unsubstituted azacycloalkylalkyl group. Suitable substituted azacycloalkyl groups include azacycloalkyl groups which have an N-alkyl substituent, preferably an N- $C_1$ - $C_4$ -alkyl substituent and more preferably an N-methyl substituent.  $R_6$  and  $R_7$  can also, together with the nitrogen atom to which they are attached, form a heterocyclic ring

system, such as a substituted or unsubstituted five or six-membered aza- or diazacycloalkyl group. Preferably, the diazacycloalkyl group includes an N-alkyl substituent, such as an N-C<sub>1</sub>-C<sub>4</sub>-alkyl substituent or, more preferably, an N-methyl substituent.

- 5 In particularly preferred embodiments, -N(R<sub>6</sub>)R<sub>7</sub> is NH<sub>2</sub> or one of the groups shown below:

10




15

Preferably, the compounds of Formula I do not include compounds wherein Z is -O-, P is hydrogen, R<sub>3</sub> and R<sub>4</sub> are both hydrogen, n is 1 and X is methylene. Preferably, the compounds of Formula I further do not include compounds wherein Z is methylene-O-,

- 5 R<sub>3</sub> and R<sub>4</sub> are both hydrogen, and n is 0.

In another aspect, the present invention is directed to angiogenesis inhibitor compounds of Formula XV,



(XV)

10

where A is a MetAP-2 inhibitory core and W is O or NR. In one embodiment, Z is -C(O)- or -alkylene-C(O)- and P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z. In this embodiment, Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is -OR, Q is not hydrogen.

15

In another embodiment, Z is -alkylene-O- or -alkylene-N(R)- and P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus. In this embodiment, Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen.

20

In the angiogenesis inhibitor compounds of Formula XV, each R is, independently, hydrogen or alkyl.

In another aspect, the invention features pharmaceutical compositions comprising the angiogenesis inhibitor compounds of Formula I or XV and a pharmaceutically acceptable carrier.

25

In yet another aspect, the invention features a method of treating an angiogenic disease, *e.g.*, cancer (such as lung cancer, brain cancer, kidney cancer, colon cancer, liver cancer, pancreatic cancer, stomach cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, and metastatic versions of any of the preceding cancers), in a subject. The method includes administering to the subject a

30

therapeutically effective amount of one or more angiogenesis inhibitor compounds of Formula I or XV.

5  
10

Figure 1 is a graph depicting the results from the rat aortic ring assay (RARA) used to test the ability of the angiogenesis inhibitor compounds of the invention to inhibit angiogenesis.


10

15  
20  
25

25

30

30



In Formula I, A is a MetAP-2 inhibitory core, W is O or NR<sub>2</sub>, and R<sub>1</sub> and R<sub>2</sub> are each, independently, hydrogen or alkyl; X is alkylene or substituted alkylene, preferably linear C<sub>1</sub>-C<sub>6</sub>-alkylene; n is 0 or 1; R<sub>3</sub> and R<sub>4</sub> are each, independently, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl or arylalkyl or substituted or unsubstituted heteroaryl or heteroalkyl. R<sub>3</sub> and R<sub>4</sub> can also, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic group; or R<sub>1</sub> and R<sub>4</sub> together can form an alkylene group; Z is -C(O)-, alkylene-C(O)- or alkylene; and P is a peptide comprising from 1 to about 100 amino acid residues attached at its amino terminus to Z or a group OR<sub>5</sub> or N(R<sub>6</sub>)R<sub>7</sub>, wherein R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are each, independently, hydrogen, alkyl, substituted alkyl, azacycloalkyl or substituted azacycloalkyl. R<sub>6</sub> and R<sub>7</sub> can also form, together with the nitrogen atom to which they are attached, a substituted or unsubstituted heterocyclic ring structure.

In another embodiment of the compounds of Formula I, W, X, n, R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> have the meanings given above for these variables; Z is -O-, -NR<sub>8</sub>-, alkylene-O- or alkylene-NR<sub>8</sub>-, where R<sub>8</sub> is hydrogen or alkyl; and P is hydrogen, alkyl, preferably normal or branched C<sub>1</sub>-C<sub>4</sub>-alkyl or a peptide consisting of from 1 to about 100 amino acid residues attached at its carboxy terminus to Z.


In compounds of Formula I, when any of R<sub>1</sub>-R<sub>8</sub> is an alkyl group, preferred alkyl groups are substituted or unsubstituted normal, branched or cyclic C<sub>1</sub>-C<sub>6</sub> alkyl groups. Particularly preferred alkyl groups are normal or branched C<sub>1</sub>-C<sub>4</sub> alkyl groups. A substituted alkyl group includes at least one non-hydrogen substituent, such as an amino group, an alkylamino group or a dialkylamino group; a halogen, such as a fluoro, chloro, bromo or iodo substituent; or hydroxyl.

When at least one of R<sub>3</sub> and R<sub>4</sub> is a substituted or unsubstituted aryl or heteroaryl group, preferred groups include substituted and unsubstituted phenyl, naphthyl, indolyl, imidazolyl and pyridyl. When at least one of R<sub>3</sub> and R<sub>4</sub> is substituted or unsubstituted arylalkyl or heteroarylalkyl, preferred groups include substituted and unsubstituted benzyl, naphthylmethyl, indolylmethyl, imidazolylmethyl and pyridylmethyl groups. Preferred substituents on aryl, heteroaryl, arylalkyl and heteroarylalkyl groups are independently selected from the group consisting of amino, alkyl-substituted amino, halogens, such as fluoro, chloro, bromo and iodo; hydroxyl groups and alkyl groups, preferably normal or branched C<sub>1</sub>-C<sub>6</sub>-alkyl groups, most preferably methyl groups. X is preferably linear C<sub>1</sub>-C<sub>6</sub>-alkylene, more preferably C<sub>1</sub>-C<sub>4</sub>-alkylene and most preferably methylene or ethylene. When Z is alkylene-C(O)-, alkylene-O- or alkylene-NR<sub>8</sub>, the alkylene group is preferably linear C<sub>1</sub>-C<sub>6</sub>-alkylene, more preferably C<sub>1</sub>-C<sub>4</sub>-alkylene and most preferably methylene or ethylene.

R<sub>6</sub> and R<sub>7</sub>, in addition to alkyl, substituted alkyl or hydrogen, can each also independently be a substituted or unsubstituted azacycloalkyl group or a substituted or

unsubstituted azacycloalkylalkyl group. Suitable substituted azacycloalkyl groups include azacycloalkyl groups which have an N-alkyl substituent, preferably an N-C<sub>1</sub>-C<sub>4</sub>-alkyl substituent and more preferably an N-methyl substituent. R<sub>6</sub> and R<sub>7</sub> can also, together with the nitrogen atom to which they are attached, form a heterocyclic ring system, such as a substituted or unsubstituted five or six-membered aza- or diazacycloalkyl group. Preferably, the diazacycloalkyl group includes an N-alkyl substituent, such as an N-C<sub>1</sub>-C<sub>4</sub>-alkyl substituent or, more preferably, an N-methyl substituent.


In particularly preferred embodiments, -N(R<sub>6</sub>)R<sub>7</sub> is NH<sub>2</sub> or one of the groups shown below:





Preferably, the compounds of Formula I do not include compounds wherein Z is  
 -O-, P is hydrogen, R<sub>3</sub> and R<sub>4</sub> are both hydrogen, n is 1 and X is methylene. Preferably,  
 5 the compounds of Formula I further do not include compounds wherein Z is methylene-  
 O-, R<sub>3</sub> and R<sub>4</sub> are both hydrogen, and n is 0.

In another embodiment, the invention provides angiogenesis inhibitor  
 compounds of Formula XV,



(XV)

- 15 where A is a MetAP-2 inhibitory core and W is O or NR. In one embodiment, Z is -  
 C(O)- or -alkylene-C(O)- and P is NHR, OR or a peptide consisting of one to about one  
 hundred amino acid residues connected at the N-terminus to Z. In this embodiment, Q is  
 hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is -OR, Q is not  
 hydrogen. Z is preferably -C(O)- or C<sub>1</sub>-C<sub>4</sub>-alkylene-C(O)-, and, more preferably, -  
 20 C(O)- or C<sub>1</sub>-C<sub>2</sub>-alkylene-C(O)-. Q is preferably linear, branched or cyclic C<sub>1</sub>-C<sub>6</sub>-alkyl,  
 phenyl or naphthyl. More preferably, Q is isopropyl, phenyl or cyclohexyl.


- In another embodiment, Z is -alkylene-O- or -alkylene-N(R)-, where alkylene is,  
 preferably, C<sub>1</sub>-C<sub>6</sub>-alkylene, more preferably C<sub>1</sub>-C<sub>4</sub>-alkylene and, most preferably, C<sub>1</sub>-C<sub>2</sub>-  
 alkylene. P is hydrogen or a peptide consisting of from one to about one hundred amino  
 25 acid residues connected to Z at the carboxyl terminus. In this embodiment, Q is  
 hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q  
 is not hydrogen. Q is preferably linear, branched or cyclic C<sub>1</sub>-C<sub>6</sub>-alkyl, phenyl or  
 naphthyl. More preferably, Q is isopropyl, phenyl or cyclohexyl.

- In the compounds of Formula XV, each R is, independently, hydrogen or alkyl.  
 30 In one embodiment, each R is, independently, hydrogen or linear, branched or cyclic C<sub>1</sub>-  
 C<sub>6</sub>-alkyl. Preferably, each R is, independently, hydrogen or linear or branched C<sub>1</sub>-C<sub>4</sub>-

alkyl. More preferably, each R is, independently, hydrogen or methyl. In the most preferred embodiments, each R is hydrogen.


In Formulas I and XV, A is a MetAP-2 inhibitory core. As used herein, a  
 5 “MetAP-2 inhibitory core” includes a moiety able to inhibit the activity of methionine aminopeptidase 2 (MetAP-2), *e.g.*, the ability of MetAP-2 to cleave the N-terminal methionine residue of newly synthesized proteins to produce the active form of the protein. Preferred MetAP-2 inhibitory cores are Fumagillin derived structures.

Suitable MetAP-2 inhibitory cores include the cores of Formula II,




(II)

where R<sup>1</sup> is hydrogen or alkoxy, preferably C<sub>1</sub>-C<sub>4</sub>-alkoxy and more preferably, methoxy. R<sup>2</sup> is hydrogen or hydroxy; and R<sup>3</sup> is hydrogen or alkyl, preferably C<sub>1</sub>-C<sub>4</sub>-alkyl and more  
 15 preferably, hydrogen. D is linear or branched alkyl, preferably C<sub>1</sub>-C<sub>6</sub>-alkyl; arylalkyl, preferably aryl-C<sub>1</sub>-C<sub>4</sub>-alkyl and more preferably phenyl-C<sub>1</sub>-C<sub>4</sub>-alkyl; or D is of the structure



where the dashed line represents a single bond or a double bond.


A can also be a MetAP-2 inhibitory core of Formula III,




(III)

Where  $R^1$ ,  $R^2$ ,  $R^3$  and D have the meanings given above for Formula II, and X is a leaving group, such as a halogen.


- 5 Examples of suitable MetAP-2 inhibitory cores include, but are not limited to, the following.




(IV)




(V)




(VI)



(VII)




(VIII)



(IX)


In each of Formulas IV-X, the indicated valence on the ring carbon is the point of attachment of the structural variable W, as set forth in Formulas I-XV. In Formula IX, p is an integer from 0 to 10, preferably 1-4. In Formulas IV, V and VI-IX, R<sub>1</sub> is hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkoxy, preferably methoxy. In Formulas IV and V, the dashed line indicates that the bond can be a double bond or a single bond. In Formula V, X represents a leaving group, such as a thioalkoxy group, a thioaryloxy group, a halogen or a dialkylsulfonium group. In Formulas IV and V, R<sub>2</sub> is H, OH, amino, C<sub>1</sub>-C<sub>4</sub>-alkylamino or di(C<sub>1</sub>-C<sub>4</sub>-alkyl)amino, preferably H. In formulas in which the stereochemistry of a particular stereocenter is not indicated, that stereocenter can have either of the possible stereochemistries, consistent with the ability of the angiogenesis inhibitor compound to inhibit the activity of MetAP-2.

In particularly preferred embodiments, A is the MetAP-2 inhibitory core of Formula X below.




(X)


As used herein, the terms "P" and "peptide" include compounds comprising from 1 to about 100 amino acid residues (*e.g.*, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more amino acid residues). In preferred embodiments, the peptide includes compounds comprising less than about 90, 80, 70, 60, 50, 40, 30, 20, or 10 amino acid residues, preferably about 1-10, 1-20, 1-30, 1-40, 1-50, 1-60, 1-70, 1-80, or 1-90 amino acid residues. The peptides may be natural or synthetically made. The amino acid residues are preferably  $\alpha$ -amino acid residues. For example, the amino acid residues can be independently selected from among the twenty naturally occurring amino acid residues, the D-enantiomers of the twenty natural amino acid residues, and may also be non-natural amino acid residues (*e.g.*, norleucine, norvaline, phenylglycine,  $\beta$ -alanine, or a peptide mimetic such as 3-amino-methylbenzoic acid). In one embodiment, the amino acid residues are independently selected from residues of Formula XI, Formula XII, and Formula XIII.



XI



XII



XIII

In Formula XI,  $X_1$  is hydrogen, a side chain of one of the twenty naturally-occurring amino acid residues, a linear, branched or cyclic  $C_1$ - $C_8$ -alkyl group, an aryl group, such as a phenyl or naphthyl group, an aryl- $C_1$ - $C_4$ -alkyl group, a heteroaryl group, such as a pyridyl, thienyl, pyrrolyl, or furyl group, or a heteroaryl- $C_1$ - $C_4$ -alkyl group; and  $X_2$  is hydrogen a linear, branched or cyclic  $C_1$ - $C_8$ -alkyl group, an aryl group, such as a phenyl or naphthyl group, an aryl- $C_1$ - $C_4$ -alkyl group or a heteroaryl group as described above for  $X_1$ . Preferably,  $X_2$  is hydrogen. In Formula XII, Y is methylene, oxygen, sulfur or NH, and a and b are each, independently, 0-4, provided that the sum of a and b is between 1 and 4. Formulas XI and XII encompass  $\alpha$ -amino acid residues having either a D or an L stereochemistry at the alpha carbon atom. One or more of the amino acid residues can also be an amino acid residue other than an  $\alpha$ -amino acid residue, such as a  $\beta$ -,  $\gamma$ - or  $\epsilon$ -amino acid residue. Suitable examples of such amino acid residues are of Formula XIII, wherein q is an integer of from 2 to about 6, and each  $X_1$  and  $X_2$  independently have the meanings given above for these variables in Formula XI.

In a preferred embodiment, the peptide used in the angiogenesis inhibitor compounds of the invention may include a site-directed sequence in order to increase the specificity of binding of the angiogenesis inhibitor compound to a cell surface of interest. As used herein, the term "site-directed sequence" is intended to include any amino acid sequence (*e.g.*, comprised of natural or non natural amino acid residues) which serves to limit exposure of the angiogenesis inhibitor compound to the periphery and/or which serves to direct the angiogenesis inhibitor compound to a site of interest, *e.g.*, a site of angiogenesis or aberrant cellular proliferation.

The peptide contained within the angiogenesis inhibitor compounds of the invention may include a peptide cleavage site for an enzyme which is expressed at sites of angiogenesis or aberrant cell proliferation, allowing tissue-selective delivery of a cell-permeable active angiogenesis inhibitor compound or fragment thereof (*e.g.*, a fragment containing the MetAP-2 inhibitory core of the angiogenesis inhibitor compound). The peptide may also include a sequence which is a ligand for a cell surface receptor which is expressed at a site of angiogenesis or aberrant cell proliferation, thereby targeting

angiogenesis inhibitor compounds to a cell surface of interest. For example, a peptide contained within the angiogenesis inhibitor compounds of the invention can include a cleavage site for a matrix metalloproteinase, or an integrin binding RGD (Arg-Gly-Asp) sequence, or a combination of both an enzyme “cleavage” sequence and a cell surface  
 5 “ligand” which serve to target the angiogenesis inhibitor compound to the membrane of an endothelial cell. However, the selection of a peptide sequence must be such that the active angiogenesis inhibitor compound is available to be delivered to the cells in which MetAP-2 inhibition is desired.

For example, a sequence that is cleaved by a matrix metalloproteinase produces a  
 10 product that contains the MetAP-2 inhibitory core, a coupling group, and a peptide fragment. Sequences are selected so that the active angiogenesis inhibitor compound, *e.g.*, the active angiogenesis inhibitor compound generated by the matrix metalloproteinase cleavage, is cell permeable. Preferably, the active angiogenesis inhibitor compound does not contain a free acid after the cleavage.

15 In one embodiment, the peptide includes a cleavage site for a matrix metalloprotease, such as matrix metalloprotease-2 (MMP-2), MMP-1, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-13 or MMP-26. Preferably, the peptide includes a cleavage site for MMP-2 or MMP-9. For example, the peptide can comprise the sequence -Pro-Leu-Gly-Xaa- (SEQ ID NO:1), where Xaa is any naturally occurring  
 20 amino acid residue consistent with matrix metalloprotease (MMP) cleavage at the Gly-Xaa bond. Xaa is preferably a hydrophobic amino acid residue, such as tryptophan, phenylalanine, methionine, leucine, isoleucine, proline, and valine.

Other suitable sequences include sequences comprising one or more of Pro-Cha-Gly-Cys(Me)-His (SEQ ID NO:2); Pro-Gln-Gly-Ile-Ala-Gly-Gln-D-Arg (SEQ ID  
 25 NO:3); Pro-Gln-Gly-Ile-Ala-Gly-Trp (SEQ ID NO:4); Pro-Leu-Gly-Cys(Me)-His-Ala-D-Arg (SEQ ID NO:5); Pro-Leu-Gly-Met-Trp-Ser-Arg (SEQ ID NO:35); Pro-Leu-Gly-Leu-Trp-Ala-D-Arg (SEQ ID NO:6); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:7); Pro-Leu-Ala-Leu-Trp-Ala-Arg (SEQ ID NO:8); Pro-Leu-Ala-Tyr-Trp-Ala-Arg (SEQ ID NO:9); Pro-Tyr-Ala-Tyr-Trp-Met-Arg (SEQ ID NO:10); Pro-Cha-Gly-Nva-His-Ala  
 30 (SEQ ID NO:11); Pro-Leu-Ala-Nva (SEQ ID NO:12); Pro-Leu-Gly-Leu (SEQ ID NO:13); Pro-Leu-Gly-Ala (SEQ ID NO:14); Arg-Pro-Leu-Ala-Leu-Trp-Arg-Ser (SEQ ID NO:15); Pro-Cha-Ala-Abu-Cys(Me)-His-Ala (SEQ ID NO:16); Pro-Cha-Ala-Gly-Cys(Me)-His-Ala (SEQ ID NO:17); Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu (SEQ ID NO:18); Pro-Lys-Pro-Leu-Ala-Leu (SEQ ID NO:19); Arg-Pro-Lys-Pro-Tyr-Ala-Nva-  
 35 Trp-Met (SEQ ID NO:20); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:21); Arg-Pro-Lys-Pro-Val-Glu-Nva-Trp-Arg (SEQ ID NO:22); and Arg-Pro-Lys-Pro-Leu-Ala-Nva-Trp (SEQ ID NO:23). These sequences identify the natural amino acid residues using the customary three-letter abbreviations; the following abbreviations

represent the indicated non-natural amino acids: Abu = L-a-aminobutyryl; Cha = L-cyclohexylalanine; Nva = L-norvaline.


In certain embodiments, P is an amino acid sequence selected from the group consisting of Ac-Pro-Leu-Gly-Met-Trp-Ala (SEQ ID NO:24); Gly-Pro-Leu-Gly-Met-  
 5 His-Ala-Gly (SEQ ID NO:25); Gly-Pro-Leu-(Me)Gly (SEQ ID NO:26); Gly-Pro-Leu-Gly (SEQ ID NO:27); Gly-Met-Gly-Leu-Pro (SEQ ID NO:28); Ala-Met-Gly-Ile-Pro (SEQ ID NO:29); Gly-Arg-Gly-Asp-(O-Me-Tyr)-Arg-Glu (SEQ ID NO:30); Gly-Arg-Gly-Asp-Ser-Pro (SEQ ID NO:31); Gly-Arg-Gly-Asp (SEQ ID NO:32); Asp-Gly-Arg; Ac-Pro-Leu-Gly-Met-Ala (SEQ ID NO:33); Ac-Arg-Gly-Asp-Ser-Pro-Leu-Gly-Met-  
 10 Trp-Ala (SEQ ID NO:34); Ac-Pro-Leu-Gly-Met-Gly (SEQ ID NO:36); Met-Trp-Ala (SEQ ID NO:37); Met-Gly (SEQ ID NO:38); Gly-Pro-Leu-Gly-Met-Trp-Ala-Gly (SEQ ID NO:39); and Gly-Arg-(3-amino-3-pyridylpropionic acid) (SEQ ID NO:40). (Ac in the foregoing sequences represents an Acetyl group).

The peptide can be attached to the MetAP-2 inhibitory core at either its N-  
 15 terminus or C-terminus. When the peptide is attached to the MetAP-2 inhibitory core at its C-terminus, the N-terminus of the peptide can be  $-NR_2R_3$ , where  $R_2$  is hydrogen, alkyl or arylalkyl and  $R_3$  is hydrogen, alkyl, arylalkyl or acyl. When the peptide is attached to the MetAP-2 inhibitory core at its N-terminus, the C-terminus can be  $-C(O)R_4$ , where  $R_4$  is -OH, -O-alkyl, -O-arylalkyl, or  $-NR_2R_3$ , where  $R_2$  is hydrogen, alkyl or arylalkyl and  
 20  $R_3$  is hydrogen, alkyl, arylalkyl or acyl. In this embodiment, the C-terminal residue can also be present in a reduced form, such as the corresponding primary alcohol.

The present invention also includes pharmaceutically acceptable salts of the angiogenesis inhibitor compounds of the invention. A "pharmaceutically acceptable salt" includes a salt that retains the desired biological activity of the parent angiogenesis  
 25 inhibitor compound and does not impart any undesired toxicological effects. Examples of such salts are salts of acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like; acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, benzoic acid, pamoic acid, alginic acid, methanesulfonic acid, naphthalenesulfonic acid, and the like. Also included are salts of cations such as sodium,  
 30 potassium, lithium, zinc, copper, barium, bismuth, calcium, and the like; or organic cations such as trialkylammonium. Combinations of the above salts are also useful.

Preferred Angiogenesis Inhibitor Compounds of Formula I












One set of particularly preferred angiogenesis inhibitor compounds of the invention includes compounds in which A is the MetAP-2 inhibitory core of Formula X, W is O or NR<sub>2</sub>, and the structure















5











is represented by the structures set forth below.










































































### Preferred Angiogenesis Inhibitor Compounds of Formula XV

A preferred subset of the angiogenesis inhibitor compounds of Formula XV








5 comprises Formula XIV shown below.









In one embodiment, W is O or NR. Z is  $-C(O)$  or  $-alkylene-C(O)-$ , preferably C1-C4-alkylene- $C(O)-$ . R is hydrogen or a C<sub>1</sub>-C<sub>4</sub>-alkyl. Q is hydrogen; linear, branched or cyclic C<sub>1</sub>-C<sub>6</sub>-alkyl; or aryl. R<sub>1</sub> is hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy or halogen. P is NH<sub>2</sub>, OR or a peptide attached to Z at its N-terminus and comprising from 1 to 100 amino acid residues independently selected from naturally occurring amino acid residues, D-enantiomers of the naturally occurring amino acid residues and non-natural amino acid residues. When Q is H, P is not NH<sub>2</sub> or OR. In preferred embodiments, W is O or NH; Q is isopropyl; R<sub>1</sub> is methoxy; P comprises from 1 to 15 amino acid residues; and the dashed line present in Formula XIV represents a double bond. In particularly preferred embodiments, W is O, and P comprises 10 or fewer amino acid residues.




In another embodiment of the compounds of Formula XIV, W is O or NR. Z is alkylene-O or alkylene-NR, preferably C1-C4-alkylene-O or C1-C4-alkylene-NR-. R is hydrogen or a C<sub>1</sub>-C<sub>4</sub>-alkyl. Q is hydrogen; linear, branched or cyclic C<sub>1</sub>-C<sub>6</sub>-alkyl; or aryl. R<sub>1</sub> is hydroxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy or halogen. P is hydrogen or a peptide attached to Z at its C-terminus and comprising from 1 to 100 amino acid residues independently selected from naturally occurring amino acid residues, D-enantiomers of the naturally occurring amino acid residues and non-natural amino acid residues. When Q is H, P is not H. In preferred embodiments, W is O or NH; Q is isopropyl; R<sub>1</sub> is methoxy; P comprises from 1 to 15 amino acid residues; and the dashed line present in Formula XIV represents a double bond. In particularly preferred embodiments, W is O, and P comprises 10 or fewer amino acid residues or P is hydrogen.




One set of particularly preferred angiogenesis inhibitor compounds of the invention is represented by the structures set forth below.






























5

### Methods of Using the Angiogenesis Inhibitor Compounds for the Treatment of Angiogenic Disease

10 In another embodiment, the present invention provides a method of treating an angiogenic disease in a subject. The method includes administering to the subject a therapeutically effective amount of an angiogenesis inhibitor compound of the present invention, thereby treating the angiogenic disease in the subject.

As used herein, the term “angiogenic disease” includes a disease, disorder, or  
 15 condition characterized or caused by aberrant or unwanted, *e.g.*, stimulated or suppressed, formation of blood vessels (angiogenesis). Aberrant or unwanted angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. Examples of angiogenic diseases include ocular disorders, *e.g.*,  
 20 diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, retrolental fibroplasia, neovascular glaucoma, rubeosis, retinal neovascularization due to macular degeneration, hypoxia, angiogenesis in the eye associated with infection or surgical intervention, ocular tumors and trachoma, and other abnormal neovascularization conditions of the eye, where neovascularization may lead to blindness; disorders  
 25 affecting the skin, *e.g.*, psoriasis and pyogenic granuloma; cancer, *e.g.*, carcinomas and sarcomas, where progressive growth is dependent upon the continuous induction of

angiogenesis by these tumor cells, lung cancer, brain cancer, kidney cancer, colon cancer, liver cancer, pancreatic cancer, stomach cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, melanoma, and metastatic versions of any of the preceding cancers; pediatric disorders, *e.g.*, angiofibroma, and hemophilic joints; blood vessel diseases such as hemangiomas, and capillary proliferation within atherosclerotic plaques; disorders associated with surgery, *e.g.*, hypertrophic scars, wound granulation and vascular adhesions; and autoimmune diseases such as rheumatoid, immune and degenerative arthritis, where new vessels in the joint may destroy articular cartilage and scleroderma.

The term angiogenic disease also includes diseases characterized by excessive or abnormal stimulation of endothelial cells, including but not limited to intestinal adhesions, Crohn's disease, atherosclerosis, scleroderma, and hypertrophic scars, *i.e.*, keloids; diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochela nivalia quintosa*) and ulcers (*Helicobacter pylori*). In addition, the angiogenesis inhibitor compounds of the present invention are useful as birth control agents (by virtue of their ability to inhibit the angiogenesis dependent ovulation and establishment of the placenta) and may also be used to reduce bleeding by administration to a subject prior to surgery.

As used herein, the term "subject" includes warm-blooded animals, preferably mammals, including humans. In a preferred embodiment, the subject is a primate. In an even more preferred embodiment, the primate is a human.

As used herein, the term "administering" to a subject includes dispensing, delivering or applying an angiogenesis inhibitor compound, *e.g.*, an angiogenesis inhibitor compound in a pharmaceutical formulation (as described herein), to a subject by any suitable route for delivery of the compound to the desired location in the subject, including delivery by either the parenteral or oral route, intramuscular injection, subcutaneous/intradermal injection, intravenous injection, buccal administration, transdermal delivery and administration by the rectal, colonic, vaginal, intranasal or respiratory tract route.

As used herein, the term "effective amount" includes an amount effective, at dosages and for periods of time necessary, to achieve the desired result, *e.g.*, sufficient to treat an angiogenic disease in a subject. An effective amount of an angiogenesis inhibitor compound, as defined herein may vary according to factors such as the disease state, age, and weight of the subject, and the ability of the angiogenesis inhibitor compound to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. An effective amount is also one in which any toxic or detrimental effects (*e.g.*, side effects) of the angiogenesis inhibitor compound are outweighed by the therapeutically beneficial effects.

A therapeutically effective amount of an angiogenesis inhibitor compound (*i.e.*, an effective dosage) may range from about 0.001 to 30 mg/kg body weight, preferably about 0.01 to 25 mg/kg body weight, more preferably about 0.1 to 20 mg/kg body weight, and even more preferably about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of an angiogenesis inhibitor compound can include a single treatment or, preferably, can include a series of treatments. In one example, a subject is treated with an angiogenesis inhibitor compound in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of an angiogenesis inhibitor compound used for treatment may increase or decrease over the course of a particular treatment.

The methods of the invention further include administering to a subject a therapeutically effective amount of an angiogenesis inhibitor compound in combination with another pharmaceutically active compound known to treat an angiogenic disease, *e.g.*, a chemotherapeutic agent such as Taxol, Paclitaxel, or Actinomycin D, or an antidiabetic agent such as Tolbutamide; or a compound that may potentiate the angiogenesis inhibitory activity of the angiogenesis inhibitor compound, such as heparin or a sulfated cyclodextrin. Other pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine, Thirteenth Edition, Eds. T.R. Harrison et al. McGraw-Hill N.Y., NY; and the Physicians Desk Reference 50th Edition 1997, Oradell New Jersey, Medical Economics Co., the complete contents of which are expressly incorporated herein by reference. The angiogenesis inhibitor compound and the pharmaceutically active compound may be administered to the subject in the same pharmaceutical composition or in different pharmaceutical compositions (at the same time or at different times).

#### Pharmaceutical Compositions of the Angiogenesis Inhibitor Compounds

The present invention also provides pharmaceutically acceptable formulations comprising one or more angiogenesis inhibitor compounds. Such pharmaceutically acceptable formulations typically include one or more angiogenesis inhibitor compounds as well as a pharmaceutically acceptable carrier(s) and/or excipient(s). As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and anti fungal agents, isotonic and absorption delaying agents,

and the like that are physiologically compatible. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the angiogenesis inhibitor compounds, use thereof in the pharmaceutical compositions is contemplated.

- 5           Supplementary pharmaceutically active compounds known to treat an angiogenic disease, *e.g.*, a chemotherapeutic agent such as Taxol, Paclitaxel, or Actinomycin D, or an antidiabetic agent such as Tolbutamide; or compounds that may potentiate the angiogenesis inhibitory activity of the angiogenesis inhibitor compound, such as heparin or a sulfated cyclodextrin, can also be incorporated into the compositions of the  
10 invention. Suitable pharmaceutically active compounds that may be used can be found in Harrison's Principles of Internal Medicine (*supra*).

- A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation),  
15 transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as  
20 ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or  
25 plastic.

- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic  
30 water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the pharmaceutical composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion  
35 medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and

by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the angiogenesis inhibitor compound in the required amount in an appropriate solvent with one or a combination of the ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the angiogenesis inhibitor compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the angiogenesis inhibitor compound plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the angiogenesis inhibitor compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also include an enteric coating. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the angiogenesis inhibitor compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the angiogenesis inhibitor compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art,

and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the angiogenesis inhibitor compounds are formulated into ointments, salves, gels, or creams as generally  
5 known in the art.

The angiogenesis inhibitor compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the angiogenesis inhibitor compounds are prepared with  
10 carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in  
15 the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811, U.S. Patent No. 5,455,044 and U.S. Patent No. 5,576,018, and U.S. Patent No.  
20 4,883,666, the contents of all of which are incorporated herein by reference.

The angiogenesis inhibitor compounds of the invention can also be incorporated into pharmaceutical compositions which allow for the sustained delivery of the angiogenesis inhibitor compounds to a subject for a period of at least several weeks to a month or more. Such formulations are described in U.S. Patent 5,968,895, the contents  
25 of which are incorporated herein by reference.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of angiogenesis inhibitor  
30 compounds calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the angiogenesis inhibitor compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such angiogenesis inhibitor  
35 compounds for the treatment of individuals.

Toxicity and therapeutic efficacy of such angiogenesis inhibitor compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and



the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Angiogenesis inhibitor compounds which exhibit large therapeutic indices are preferred. While angiogenesis inhibitor compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such angiogenesis inhibitor compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such angiogenesis inhibitor compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any angiogenesis inhibitor compounds used in the methods of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (*i.e.*, the concentration of the angiogenesis inhibitor compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

#### Assays for Detecting the Activity of the Angiogenesis Inhibitor Compounds

The angiogenesis inhibitor compounds of the invention may be tested for their ability to modulate (*e.g.*, inhibit or stimulate) angiogenesis in a variety of well known assays, *e.g.*, the rat aortic ring angiogenesis inhibition assay (described herein in Example 27) or in a chorioallantoic membrane (CAM) assay.

The CAM assay may be performed essentially as described in Liekens S. et al. (1997) *Oncology Research* 9: 173-181, the contents of which are incorporated herein by reference. Briefly, fresh fertilized eggs are incubated for 3 days at 37°C. On the third day, the shell is cracked and the egg is placed into a tissue culture plate and incubated at 38°C. For the assay, the angiogenesis inhibitor compound to be tested is attached on a matrix of collagen on a nylon mesh. The mesh is then used to cover the chorioallantoic membrane and the eggs are incubated at 37°C. If angiogenesis occurs, new capillaries form and grow through the mesh within 24 hours. The ability of the angiogenesis inhibitor compound (at various concentrations) to modulate, *e.g.*, inhibit, angiogenesis, *e.g.*, FGF-induced angiogenesis, may then be determined.

The angiogenesis inhibitor compounds of the invention may also be tested for their ability to modulate (*e.g.*, inhibit or stimulate) human endothelial cell growth.

Human umbilical vein endothelial cells (HUVE) may be isolated by perfusion of an umbilical vein with a trypsin-containing medium. HUVE may then be cultured in GIT medium (Diago Eiyu Kagaku, Co., Japan) supplemented with 2.5% fetal bovine serum and 2.0 ng/ml of recombinant human basic fibroblast growth factor (rbFGF,

- 5 Biotechnology Research Laboratories, Takeda, Osaka, Japan) at 37°C under 5% CO<sub>2</sub> and 7% O<sub>2</sub>. HUVE are then plated on 96-well microtiter plates (Nunc, 1-67008) at a cell density of  $2 \times 10^3$  /100  $\mu$ l of medium. The following day, 100  $\mu$ l of medium containing rbFGF (2 ng/ml at the final concentration) and each angiogenesis inhibitor compound at various concentrations may be added to each well. The angiogenesis inhibitor compounds are dissolved in dimethylsulfoxide (DMSO) and then diluted with culture medium so that the final DMSO concentration does not exceed 0.25%. After a 5-day culture, medium is removed, 100  $\mu$ l of 1 mg/ml of MTT (3-(4,5-dimethyl-2-thiazolyl)- 2,5-diphenyl-2 H-tetrazolium bromide) solution is added to the wells, and microtiters are kept at 37°C for 4 hours. Then, 100  $\mu$ l of 10% sodium dodecyl sulfate (SDS) solution is added to wells, and the microtiters are kept at 37°C for 5-6 hours. To determine the effects of the angiogenesis inhibitor compound on cell number, the optical density (590  $\mu$ m) of each well is measured using an optical densitometer.

- The ability of the angiogenesis inhibitor compounds of the invention to modulate capillary endothelial cell migration *in vitro* may also be tested using the Boyden chamber assay (as described in Falk *et al.* (1980) *J. Immunol. Meth.* 33:239-247, the contents of which are incorporated herein by reference). Briefly, bovine capillary endothelial cells are plated at  $1.5 \times 10^4$  cells per well in serum-free DMEM (Dulbecco's Modified Eagle's Medium) on one side of nucleopore filters pre-coated with fibronectin (7.3  $\mu$ g fibronectin/ml PBS). An angiogenesis inhibitor compound is dissolved in ethanol and diluted in DMEM so that the final concentration of ethanol does not exceed 0.01%. Cells are exposed to endothelial mitogen (Biomedical Technologies, Mass.) at 200  $\mu$ g/ml and different concentrations of the angiogenesis inhibitor compound in serum-free DMEM for 4 hours at 37°C. At the end of this incubation, the number of cells that migrate through 8 $\mu$  pores in the filters is determined by counting cells with an ocular grid at 100x in quadruplicate.

- The ability of the angiogenesis inhibitor compounds of the invention to modulate tumor growth may be tested *in vivo*. An animal model, *e.g.*, a C57BL/6N mouse with a mouse reticulum cell sarcoma (M 5076) intraperitoneally transplanted therein, may be used. The tumor cells in ascites can be collected by centrifugation, and suspended in saline. The cell suspension ( $2 \times 10^6$  cells/100  $\mu$ l/mouse) is inoculated into the right flanks of mice. Tumor-bearing mice are then subcutaneously treated with the angiogenesis inhibitor compound (at various concentrations suspended in 5% arabic gum solution containing 1% of ethanol) for 12 days beginning one day after the tumor inoculation.

The tumor growth may be determined by measuring tumor size in two directions with calipers at intervals of a few days.

Finally, the ability of the angiogenesis inhibitor compounds of the invention to modulate the activity of MetAP2 may be tested as follows. Recombinant human MetAP2 may be expressed and purified from insect cells as described in Li and Chang, (1996) *Biochem. Biophys. Res. Commun.* 227:152-159. Various amounts of angiogenesis inhibitor compound is then added to buffer H (10 mM Hepes, pH 7.35, 100 mM KCl, 10% glycerol, and 0.1 M Co<sup>2+</sup>) containing 1nM purified recombinant human MetAP2 and incubated at 37°C for 30 minutes. To start the enzymatic reaction a peptide containing a methionine residue, *e.g.*, Met-Gly-Met, is added to the reaction mixture (to a concentration of 1 mM). Released methionine is subsequently quantified at different time points (*e.g.*, at 0, 2, 3, and 5 minutes) using the method of Zou *et al.* (1995) *Mol. Gen. Genetics* 246:247-253).

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and the Sequence Listing, are hereby incorporated by reference.

## EXAMPLES

### Synthetic methods

Compounds of the invention can be prepared using one or more of the following general methods.

General Procedure A: To a mixture of carbonic acid-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester 4-nitro-phenyl ester<sup>1</sup> (1, 0.47 mmol; Han, C. K.; Ahn, S. K.; Choi, N. S.; Hong, R. K.; Moon, S. K.; Chun, H. S.; Lee, S. J.; Kim, J. W.; Hong, C. I.; Kim, D.; Yoon, J. H.; No, K. T. *Biorg. Med. Chem. Lett.* 2000, 10, 39-43) and amine (2.35 mmol) in EtOH (9 mL) was added dropwise, diisopropyl ethyl amine (2.35 mmol). After 3-18 hours, the ethanol was removed in vacuo and the crude material was dissolved into EtOAc (10 mL) and washed with H<sub>2</sub>O (2 x 5 mL), and then brine (5 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent removed in vacuo. Purification via flash chromatography (2-5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded product.


General Procedure B, Part I: A solution of (3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino)-acetic acid<sup>2</sup> (**2**, 0.11 mmol; U.S. Patent No. 6,017,954) in DMF (1 mL) was added to a 10 mL round bottomed flask containing swelled PS-DCC (0.28 mmol). In a separate vessel, the peptide (0.04 mmol) was dissolved into DMF (0.5 mL) and neutralized with NMM (0.04 mmol). After 1 hour, the solution of peptide was added to the pre-activated acid, and the reaction was continued for 5-18 hours. The resin was removed by filtration, washed with DMF (0.5 mL) and the solvent removed in vacuo. Purification via HPLC (CH<sub>3</sub>CN/H<sub>2</sub>O) afforded the product.

General Procedure B, Part II: A solution of the product in Part I (0.009 mmol) was dissolved into MeOH (1 mL) and was treated with Pd/C (2 mg), then subjected to a H<sub>2</sub> atmosphere (38 psi) for 24 hours. The mixture was then filtered through Celite, washed with MeOH (0.5 mL) and the solvent removed in vacuo. Purification via HPLC (CH<sub>3</sub>CN/H<sub>2</sub>O) afforded the product as a white solid.

General Procedure C: (1-Hydroxymethyl-methyl-propyl)-carbamic acid (3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester (Example 7, 189 mg, 0.46 mmol), acid (0.46 mmol) and DMAP (0.69 mmol) were dissolved into anhydrous CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and treated with diisopropylcarbodiimide (0.46 mmol). After 7-18 hours, the solvent was removed in vacuo and purification via flash chromatography (MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product.

### Example 1

2-[(3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino]-3-methyl-butyric acid methyl ester




General procedure A was followed using **1** (31 mg, 0.07 mmol), L-valine methyl ester hydrochloride (58 mg, 0.35 mmol), and DIEA (60  $\mu$ L, 0.35 mmol) in EtOH (2 mL). Purification via flash chromatography (1% MeOH/ $\text{CH}_2\text{Cl}_2$ ) afforded the product as a clear oil (10 mg, 0.02 mmol, 33% yield);  $R_f$  = 0.60 (20% EtOAc/ $\text{CH}_2\text{Cl}_2$ ); LRMS ( $m/z$ )

5  $[\text{M}+1]^+$  440.3 (calculated for  $\text{C}_{23}\text{H}_{38}\text{NO}_7$ , 440.3).

### Example 2

2-((3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-((2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl)-1-oxa-spiro[2.5]oct-6-yl)oxycarbonylamino}-3-methyl-butyrac acid methyl ester

10




General procedure A was followed using **1** (41 mg, 0.09 mmol) and D-valine methyl ester hydrochloride (77 mg, 0.45 mmol), and DIEA (80  $\mu$ L, 0.45 mmol) in EtOH (2 mL). Purification via flash chromatography (1% MeOH/ $\text{CH}_2\text{Cl}_2$ ) afforded the product as a clear oil (18 mg, 0.04 mmol, 45% yield);  $R_f$  = 0.39 (20% EtOAc/ $\text{CH}_2\text{Cl}_2$ ); LRMS ( $m/z$ )  $[\text{M}+1]^+$  440.3 (calculated for  $\text{C}_{23}\text{H}_{38}\text{NO}_7$ , 440.3).

15

### Example 3

2-((3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-((2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl)-1-oxa-spiro[2.5]oct-6-yl)oxycarbonylamino}-4-methyl-pentanoic acid methyl ester

20



General procedure A was followed using **1** (23 mg, 0.05 mmol), D-leucine methyl ester hydrochloride (47 mg, 0.25 mmol), and DIEA (45  $\mu$ L, 0.25 mmol) in EtOH


25

(2 mL). Purification via flash chromatography (1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a clear oil (19 mg, 0.04 mmol, 83% yield); *R*<sub>f</sub> = 0.22 (15% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>); LRMS (*m/z*) [M+1]<sup>+</sup> 454.3 (calculated for C<sub>24</sub>H<sub>40</sub>NO<sub>7</sub>, 454.3).

5

**Example 4**

{(3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-phenyl-acetic acid methyl ester




10

General procedure A was followed using **1** (37 mg, 0.08 mmol), D-phenyl glycine methyl ester hydrochloride (83 mg, 0.40 mmol), and DIEA (72 μL, 0.40 mmol) in EtOH (2 mL). Purification via flash chromatography (1% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a clear oil (32 mg, 0.07 mmol, 82% yield); *R*<sub>f</sub> = 0.41 (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS (*m/z*) [M+1]<sup>+</sup> 474.3 (calculated for C<sub>26</sub>H<sub>36</sub>NO<sub>7</sub>, 474.3).

15

**Example 5**

(1-Carbamoyl-2-methyl-propyl)-carbamic acid-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




20

General procedure A was followed using **1** (55 mg, 0.12 mmol), D-valine amide hydrochloride (93 mg, 0.62 mmol), and DIEA (110 μL, 0.62 mmol) in EtOH (2 mL). Purification via flash chromatography (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a clear oil (42 mg, 0.10 mmol, 80% yield); *R*<sub>f</sub> = 0.19 (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS (*m/z*) [M+1]<sup>+</sup> 425.5 (calculated for C<sub>22</sub>H<sub>37</sub>N<sub>2</sub>O<sub>6</sub>, 425.5).

**Example 6**

- 5 (1-Carbamoyl-2-methyl-propyl)-carbamic acid-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




- 10 The compound in Example 4 (18 mg, 0.04 mmol) was dissolved into anhydrous MeOH (1.5 mL) and treated with Pd-C (2 mg) under a H<sub>2</sub> atmosphere. After 12 hours, the reaction was filtered through Celite and the solvent removed in vacuo to afford the product as a clear oil (18 mg, 0.04 mmol, 100% yield); *R*<sub>f</sub> = 0.21 (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS (*m/z*) [*M*+1]<sup>+</sup> 427.5 (calculated for C<sub>22</sub>H<sub>39</sub>N<sub>2</sub>O<sub>6</sub>, 427.5).

15

**Example 7**


(1-Hydroxymethyl-2-methyl-propyl)-carbamic acid-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*,3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester



- 20 General procedure A was followed using **1** (290 mg, 0.65 mmol), D-valinol (337 mg, 3.25 mmol), and DIEA (560 μL, 3.25 mmol) in EtOH (5 mL). Purification via flash chromatography (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a clear oil (200 mg, 0.49 mmol, 75% yield); *R*<sub>f</sub> = 0.26 (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS (*m/z*) [*M*+1]<sup>+</sup> 412.5 (calculated for C<sub>22</sub>H<sub>38</sub>NO<sub>6</sub>, 412.5).

25


5 2-{{(3*R*, 4*S*, 5*S*, 6*R* )-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino}-3,3-dimethyl-butylric acid methyl ester



General procedure A was followed using **1** (65 mg, 0.15 mmol), D-tBu glycine methyl ester hydrochloride (132 mg, 0.73 mmol), and DIEA (127  $\mu$ L, 0.73 mmol) in EtOH (8 mL). Purification via flash chromatography (10% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a clear oil (10 mg, 0.02 mmol, 15% yield);  $R_f$  = 0.22 (10% EtOAc/CH<sub>2</sub>Cl<sub>2</sub>); LRMS ( $m/z$ ) [M+1]<sup>+</sup> 454.5 (calculated for C<sub>24</sub>H<sub>40</sub>NO<sub>7</sub>, 454.5).

## 20

Cyclohexyl-2-[(3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl)oxycarbonylamino]-acetic acid methyl ester




General procedure A was followed using **1** (65 mg, 0.15 mmol), D-cyclohexyl glycine methyl ester hydrochloride (207 mg, 0.73 mmol), and DIEA (127  $\mu$ L, 0.73 mmol) in EtOH (7 mL). Purification via flash chromatography (10% EtOAc/ $\text{CH}_2\text{Cl}_2$ ) afforded the product as a clear oil (20 mg, 0.04 mmol, 28% yield);  $R_f$  = 0.22 (10% EtOAc/ $\text{CH}_2\text{Cl}_2$ ); LRMS ( $m/z$ )  $[\text{M}+1]^+$  480.3 (calculated for  $\text{C}_{26}\text{H}_{42}\text{NO}_7$ , 480.3).



**Example 10**

- 5 2-[(3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxy-carbonylamino]-3-methyl-pentanoic acid methyl ester




- 10 General procedure A was followed using **1** (65 mg, 0.15 mmol), D-isoleucine methyl ester hydrochloride (132 mg, 0.73 mmol), and DIEA (127  $\mu$ L, 0.73 mmol) in EtOH (7 mL). Purification via flash chromatography (10% EtOAc/ $\text{CH}_2\text{Cl}_2$ ) afforded the product as a clear oil (20 mg, 0.04 mmol, 30% yield);  $R_f$  = 0.20 (10% EtOAc/ $\text{CH}_2\text{Cl}_2$ ); LRMS ( $m/z$ )  $[\text{M}+1]^+$  454.5 (calculated for  $\text{C}_{24}\text{H}_{40}\text{NO}_7$ , 454.5).

15

**Example 11**

- [1-(1-Carbamoyl-2-hydroxy-ethyl-carbamoyl)-2-methyl-propyl]-carbamic acid-(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester
- 20




General procedure A was followed using **1** (74 mg, 0.17 mmol), H-D-vS- $\text{NH}_2 \cdot \text{TFA}$  (262 mg, 0.83 mmol), and DIEA (140  $\mu$ L, 0.83 mmol) in EtOH (5 mL). Purification via HPLC (60%  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ ) afforded the as a white solid (34 mg, 0.07

mmol, 40% yield);  $R_f = 0.21$  (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS ( $m/z$ ) [M+1]<sup>+</sup> 512.5 (calculated for C<sub>25</sub>H<sub>42</sub>N<sub>3</sub>O<sub>8</sub>, 512.3).

### Example 12

- 5 2-(3-((3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl}-ureido)-3-methyl-butylamide




- (3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-ylamine (**3**; PCT Publication No. WO 99/59987) was prepared according to the published procedure. To a solution of crude **3** (29 mg, 0.1 mmol), DIEA (21 mL, 0.1 mmol) and DMAP (2 mg) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) cooled to 0 °C was added *p*-NO<sub>2</sub> phenyl chloroformate (25 mg, 0.12 mmol). After 45 minutes, the reaction was warmed to room temperature and a solution of H-D-val-NH<sub>2</sub>•HCl (40 mg, 0.15 mmol) in EtOH (1 mL) and DIEA (35 μL, 0.2 mmol) was added.
- 15 The reaction was continued for 1 hour, then was concentrated in vacuo, taken up into EtOAc (15 mL), and washed with dilute HCl<sub>aq</sub> (2 x 15 mL), H<sub>2</sub>O (2 x 15 mL) and brine (15 mL). Purification via flash chromatography (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a white solid (6 mg, 0.014 mmol, 13% yield from **3**);  $R_f = 0.12$  (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS ( $m/z$ ) [M+1]<sup>+</sup> 424.4 (calculated for C<sub>22</sub>H<sub>38</sub>N<sub>3</sub>O<sub>5</sub>, 424.4).

20

### Example 13

N-Carbamoyl (ID#31) 3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




General Procedure B, Part I was followed using **2** (41 mg, 0.11 mmol), PS-DCC (256 mg, 0.28 mmol) in DMF (1 mL) and H-RGD(Bn)S(OBn)P-NH<sub>2</sub>•2TFA (37 mg, 0.04 mmol), NMM (4 µL, 0.04 mmol) in DMF (0.5 mL). Purification via HPLC (70%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white flocculent solid (9.3 mg, 0.009 mmol, 17%yield); LRMS (*m/z*) [M+1]<sup>+</sup> 1075.4 (calculated for C<sub>53</sub>H<sub>75</sub>N<sub>10</sub>O<sub>14</sub>, 1075.5).

General Procedure, Part II was followed using the product in Part I (9.3 mg, 0.009 mmol) and Pd/C (2 mg) in MeOH (1 mL), and a H<sub>2</sub> atmosphere (38 psi) for 24 hours. Purification via HPLC (55%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (5 mg, 0.006 mmol, 65% yield); LRMS (*m/z*) [M+1]<sup>+</sup> 897.3 (calculated for C<sub>39</sub>H<sub>65</sub>N<sub>10</sub>O<sub>14</sub>, 897.5 ).

### Example 14

- 15 N-Carbamoyl (ID#30) 3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-butyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




General Procedure, Part I was followed using **2** (38 mg, 0.10 mmol) and PS-DCC (238 mg, 0.25 mmol) in DMF (1 mL), H-RGD(Bn)Y(OMe)RE(Bn)-NH<sub>2</sub>•3TFA (35 mg, 0.03 mmol) and NMM (3 µL, 0.03 mmol) in DMF (0.5 mL). Purification via HPLC (70%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white flocculent solid (4.0 mg, 0.002 mmol, 8%yield); LRMS (*m/z*) [M+2/2]<sup>+</sup> 677.6 (calculated for C<sub>66</sub>H<sub>92</sub>N<sub>14</sub>O<sub>17</sub>, 677.8).

General Procedure, Part II was followed using the product in Part I (3.0 mg, 0.002 mmol) and Pd/C (2 mg) in MeOH (1 mL), under a H<sub>2</sub> atmosphere (38 psi) for 24 hours. Purification via HPLC (55%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (3.3 mg, 0.0027 mmol, 94% yield); LRMS (*m/z*) [M+2/2]<sup>+</sup> 588.5 (calculated for C<sub>52</sub>H<sub>82</sub>N<sub>14</sub>O<sub>17</sub>, 588.7).

## 5

0




15

20

## 25

2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




General Procedure B, Part I was followed using **2** (65 mg, 0.17 mmol), PS-DCC (405 mg, 0.43 mmol), and HOBt (34 mg, 0.26 mmol) in DMF (1 mL), and H-RG(pyridyl)D-OMe (43 mg, 0.06 mmol) and NMM (7  $\mu$ L, 0.06 mmol) in DMF (0.5 mL). Purification via HPLC (50% CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (15 mg, 0.02 mmol, 34%yield); LRMS (*m/z*) 773.2 (calculated for C<sub>34</sub>H<sub>55</sub>N<sub>4</sub>O<sub>10</sub>, 773.4).

The product of Part I (11 mg, 0.01 mmol) was dissolved into THF:MeOH:H<sub>2</sub>O (2:1:1, 500  $\mu$ L) and treated with LiOH•H<sub>2</sub>O (1.2 mg, 0.02 mmol) for 2 hours. The crude material was diluted with EtOAc (5 mL) and acidified with dilute HCl (10 mL). The aqueous phase was washed with additional EtOAc (2 x 5 mL), the combined organic extracts dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent removed in vacuo. Purification via HPLC (30% CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (2 mg, 0.003 mmol, 19% yield). LRMS (*m/z*) 745.3 (calculated for C<sub>33</sub>H<sub>53</sub>N<sub>4</sub>O<sub>10</sub>, 745.4).

15

**Example 17**

N-Carbamoyl (ID#39) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




20

General procedure B, Part I was followed using **2** (25 mg, 0.07 mmol) and PS-DCC (155 mg, 0.16 mmol) in DMF (1 mL), and H-PLGMWAG-NH<sub>2</sub> (20 mg, 0.03 mmol) and NMM (3  $\mu$ L, 0.03 mmol) in DMF (0.5 mL). Purification via HPLC (70%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (1.4 mg, 0.001 mmol, 5%yield); LRMS (*m/z*) [M+1]<sup>+</sup> 1095.6 (calculated for C<sub>53</sub>H<sub>79</sub>N<sub>10</sub>O<sub>13</sub>S, 1095.6).

**Example 18**

N-Carbamoyl (ID#26) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester



5

General Procedure B, Part I was followed using **2** (69 mg, 0.18 mmol), PS-DCC (429 mg, 0.45 mmol) and HOBT (21 mg, 0.18 mmol) in DMF (1 mL), and H-PL(N-Me)G-OMe (31 mg, 0.07 mmol) and NMM (8  $\mu$ L, 0.07 mmol) in DMF (0.5 mL). Purification via HPLC (70%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (27 mg, 0.04 mmol, 59%yield); LRMS (*m/z*) [M+1]<sup>+</sup> 679.4 (calculated for C<sub>34</sub>H<sub>55</sub>N<sub>4</sub>O<sub>10</sub>, 679.4).

10


The product of Part I (27 mg, 0.04 mmol) was dissolved into THF:MeOH:H<sub>2</sub>O (2:1:1, 1.5 mL) and treated with LiOH·H<sub>2</sub>O (4 mg, 0.10 mmol) for 1 hour. The solution was acidified to pH 3 using 0.1 N HCl, and the MeOH and THF removed in vacuo.

15

Purification via HPLC (60% CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (6 mg, 0.01 mmol, 23% yield). LRMS (*m/z*) 665.4 (calculated for C<sub>33</sub>H<sub>53</sub>N<sub>4</sub>O<sub>10</sub>, 665.4).

**Example 19**

20 N-Carbamoyl (ID#27) (3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yl ester




General Procedure B, Part I was followed using **2** (44 mg, 0.12 mmol), PS-DCC (276 mg, 0.29 mmol) and HOBt (27 mg, 0.23 mmol) in DMF (1 mL), and H-PLG-OMe (20 mg, 0.05 mmol) and NMM (5  $\mu$ L, 0.05 mmol) in DMF (0.5 mL). Purification via HPLC (90%CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (13 mg, 0.02 mmol, 43%yield); LRMS (*m/z*) [M+1]<sup>+</sup> 664.4 (calculated for C<sub>34</sub>H<sub>52</sub>N<sub>4</sub>O<sub>10</sub>, 664.4).

The product in Part I (27 mg, 0.04 mmol) was dissolved into THF:MeOH:H<sub>2</sub>O (2:1:1, 790  $\mu$ L) and treated with LiOH•H<sub>2</sub>O (1.2 mg, 0.03 mmol) for 2 hours. The solution was acidified to pH 3 using 0.1 N HCl, and the MeOH and THF removed in vacuo. Purification via HPLC (90% CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (1.8 mg, 0.003 mmol, 15% yield). LRMS (*m/z*) 650.4 (calculated for C<sub>32</sub>H<sub>50</sub>N<sub>4</sub>O<sub>10</sub>, 650.4).

### Example 20


(ID#24)-(2*R*-(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester



General Procedure C was followed using the compound in Example 7 (189 mg, 0.46 mmol), Ac-PLGMWA-OH (329 mg, 0.46 mmol), DMAP (84 mg, 0.69 mmol) and DIC (72  $\mu$ L, 0.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). After 18 hours, the solvent was removed in vacuo and purification via flash chromatography (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a white solid (357 mg, 0.32 mmol, 70% yield); R<sub>f</sub> = 0.18 (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS (*m/z*) [M+1]<sup>+</sup> 1110.3 (calculated for C<sub>56</sub>H<sub>85</sub>N<sub>8</sub>O<sub>13</sub>S, 1110.3).

### Example 21


(ID#36)-(2*R*-(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester



General Procedure C was followed using the compound in Example 7 (61 mg, 0.15 mmol), Ac-PLGMG-OH (92 mg, 0.18 mmol), DMAP (22 mg, 0.18 mmol) and DIC (28  $\mu$ L, 0.18 mmol) in  $\text{CH}_2\text{Cl}_2$  (2 mL). After 7 hours, the solvent was removed in vacuo and purification via flash chromatography (3% MeOH/ $\text{CH}_2\text{Cl}_2$ ) afforded the product as a white solid (61 mg, 0. mmol, 45% yield);  $R_f$  = 0.20 (5% MeOH/ $\text{CH}_2\text{Cl}_2$ ); LRMS ( $m/z$ )  $[\text{M}+1]^+$  909.7 (calculated for  $\text{C}_{44}\text{H}_{73}\text{N}_6\text{O}_{12}\text{S}$ , 909.5).

#### Example 22

(ID#37)-(2*R*-(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester




General Procedure C was followed using the compound in Example 7 (79 mg, 0.19 mmol), Fmoc-MWA-OH (121 mg, 0.19 mmol) and DMAP (4 mg, 0.03 mmol) and DIC (30  $\mu$ L, 0.19 mmol) in  $\text{CH}_2\text{Cl}_2$  (2 mL). After 11 hours, the solvent was removed in vacuo and purification via flash chromatography (2% MeOH/ $\text{CH}_2\text{Cl}_2$ ) afforded the product as a white solid (128 mg, 0.12 mmol, 65% yield); LRMS ( $m/z$ )  $[\text{M}+1]^+$  1022.9 (calculated for  $\text{C}_{44}\text{H}_{73}\text{N}_6\text{O}_{12}\text{S}$ , 1022.5).



- The product from General Procedure C (above) (54 mg, 0.05 mmol) was dissolved into anhydrous  $\text{CH}_2\text{Cl}_2$  (3 mL) cooled to  $0^\circ\text{C}$ , then treated with a gentle stream of  $\text{NH}_3(\text{g})$  for 15 minutes. The reaction was sealed and continued at  $0^\circ\text{C}$  for 36 hours. The solvent was removed in vacuo, and the crude residue acidified with
- 5  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (0.075% TFA) (5 mL). Purification via HPLC (70%  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ /0.075% TFA) afforded the product as a white solid (2 mg, 0.003 mmol, 5% yield); LRMS ( $m/z$ )  $[\text{M}+1]^+$  800.6 (calculated for  $\text{C}_{41}\text{H}_{62}\text{N}_5\text{O}_9\text{S}$ , 800.5).

### Example 23

- 10 (ID#38)-(2*R*-(3*R*, 4*S*, 5*S*, 6*R*) 5-methoxy-4-[(2*R*,3*R*)2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl} amino-3-methyl-butanol) ester




- General Procedure C was followed using the compound in Example 7 (76 mg, 0.18 mmol), Fmoc-MG-OH (79 mg, 0.18 mmol) and DMAP (4 mg, 0.03 mmol) and VDIC (29  $\mu\text{L}$ , 0.18 mmol) in  $\text{CH}_2\text{Cl}_2$  (2 mL). After 10 hours, the solvent was removed in vacuo and purification via flash chromatography (2%  $\text{MeOH}/\text{CH}_2\text{Cl}_2$ ) afforded the product as a white solid (128 mg, 0.12 mmol, 65% yield); LRMS ( $m/z$ )  $[\text{M}+1]^+$  822.6 (calculated for  $\text{C}_{44}\text{H}_{60}\text{N}_3\text{O}_{10}\text{S}$ , 822.5).

- 20 The product from General Procedure C (above) (42 mg, 0.05 mmol) was dissolved into anhydrous  $\text{CH}_2\text{Cl}_2$  (3 mL) cooled to  $0^\circ\text{C}$ , then treated with a gentle stream of  $\text{NH}_3(\text{g})$  for 15 minutes. The reaction was sealed and continued at  $0^\circ\text{C}$  for 36 hours. The solvent was removed in vacuo, and the crude residue acidified with  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$  (0.075% TFA) (5 mL). Purification via HPLC (70%  $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ /0.075%
- 25 TFA) afforded the product as a white solid (2 mg, 0.003 mmol, 5% yield); LRMS ( $m/z$ )  $[\text{M}+1]^+$  600.4 (calculated for  $\text{C}_{29}\text{H}_{50}\text{N}_3\text{O}_8\text{S}$ , 600.4).

**Example 24**

- 5 2-[(3*R*, 4*S*, 5*S*, 6*R*)-5-Methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonylamino]-3-methyl-but-2-ynoic acid




- 10 The compound in Example 2 (9 mg, 0.02 mmol) was dissolved into THF:MeOH:H<sub>2</sub>O (1 mL) and treated with LiOH·H<sub>2</sub>O (2 mg, 0.05 mmol). After 2 hours, the reaction was partitioned between EtOAc (5 mL) and dilute HCl (5 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent removed in vacuo. Purification via HPLC (85% CH<sub>3</sub>CN/H<sub>2</sub>O/0.075% TFA) afforded the product as a white solid (0.58 mg, 0.001 mmol, 6% yield); LRMS (*m/z*) [M+1]<sup>+</sup> 426.4 (calculated for C<sub>22</sub>H<sub>36</sub>NO<sub>7</sub>, 426.5).

15

**Example 25**

- (ID#34)-(2*R*)-[(3*R*, 4*S*, 5*S*, 6*R*)-5-methoxy-4-[(2*R*, 3*R*)-2-methyl-3-(3-methyl-but-2-enyl)-oxiranyl]-1-oxa-spiro[2.5]oct-6-yloxycarbonyl] amino-3-methyl-butanol ester



- 20 General Procedure C was followed using the compound in Example 7 (41 mg, 0.10 mmol), Ac-PLGMG-OH (63 mg, 0.12 mmol), DMAP (15 mg, 0.12 mmol) and DIC (19  $\mu$ L, 0.12 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL). After 7 hours, the solvent was removed in vacuo and purification via flash chromatography (3% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded the product as a

white solid (43 mg, 0.05 mmol, 47% yield);  $R_f = 0.21$  (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub>); LRMS ( $m/z$ ) [ $M+1$ ]<sup>+</sup> 923.7 (calculated for C<sub>45</sub>H<sub>75</sub>N<sub>6</sub>O<sub>12</sub>S, 923.5).

5

### Example 26

The angiogenesis inhibitor compounds of the invention were tested for their ability to modulate human endothelial cell growth and for their ability to modulate the activity of MetAP2. The MetAP2 enzyme assay was performed essentially as described in Turk, B. *et al.* (1999) *Chem. & Bio.* 6: 823-833, the entire contents of which are incorporated herein by reference. The bovine aortic endothelial cell growth assay (Baec assay) was performed essentially as described in Turk, B. *et al.* (*supra*), the entire contents of which are incorporated herein by reference.

For the human endothelial cell growth assay, human umbilical vein endothelial cells (HUVEC) were maintained in Clonetics endothelial growth medium (EGM) in a 37 °C humidified incubator. Cells were detached with trypsin and pelleted by centrifugation at 300 x g for 5 minutes at room temperature. HUVEC were added to 96-well plates at 5,000 cells/well. After incubating for 6 hours, the medium was replaced with 0.2 ml fresh EGM supplemented with 0.5 nM bFGF and the desired concentration of test angiogenesis inhibitor compound. Test angiogenesis inhibitor compounds were initially dissolved in ethanol at stock concentrations of either 10 mM or 0.1 mM, and subsequently diluted in EGM to obtain concentrations from 1 pM to 10 µM. After 48 hours at 37 °C, the medium was replaced with fresh bFGF-supplemented EGM and test angiogenesis inhibitor compound. Following incubation for an additional 48 hours at 37 °C MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) was added to 1 mg/ml. After 2-4 hours at 37 °C the medium was replaced with 0.1 ml/well isopropanol. The plates were placed on a shaker for 15 minutes at room temperature and analyzed in a Labsystems Multiskan plate spectrophotometer at an optical density of 570 nm.

The results of the assays, set forth below in Tables I-III, demonstrate that the angiogenesis inhibitor compounds of the invention have excellent MetAP2 inhibitory activity and are able to inhibit endothelial cell growth at the picomolar range.

**Table I. MetAP2 Assay**

Example	IC <sub>50</sub> (nM)
1	4.7
2	2
3	5.5
4	2.7

13	2.9
14	4000
17	16.7

**Table II.** Huvec Assay


Example	IC <sub>50</sub> (pM)
1	18
2	40
3	38
4	36
5	93
13	(>10 $\mu$ M)
14	(>10 $\mu$ M)
15	(>10 $\mu$ M)
17	(95 nM)
18	(>100 nM)
19	(>100 nM)
24	5444

**5 Table III.** Baec Assay


Example	IC <sub>50</sub> (pM)
1	17
2	48
3	118
4	35
5	46
6	220
7	128
8	313
9	165
10	179
11	(>100 nM)
16	(>100 nM)
19	(>100 nM)
22	326
23	207

The identity of the angiogenesis inhibitor compounds used in each of the experiments is shown in Tables IV and V below.

5

**Table IV.**

Example	ID#	Sequence
13	31	X-GlyArgGlyAspSerPro-NH <sub>2</sub>
14	30	X-GlyArgGlyAspTyr(OMe)Arg Glu-NH <sub>2</sub>
15	32	X-GlyArgGlyAsp-NH <sub>2</sub>
16	40	X-GlyArg{3-amino-(3-pyridyl)}-propionic acid
17	39	X-GlyProLeuGlyMetTrpAlaGly-NH <sub>2</sub>
18	26	X-GlyProLeuSar-OH
19	27	X-GlyProLeuGly-OH

10 **Table V.**

Example	ID#	Sequence
20	24	Ac-ProLeuGly-MetTrpAla-Y
21	36	Ac-ProLeuGlyMetGly-Y
22	37	H-MetTrpAla-Y
23	38	H-MetGly-Y

*Example 27*

The angiogenesis inhibitor compounds of the invention were also tested for their ability to modulate angiogenesis using the rat aortic ring assay (RARA). For this assay, male Sprague-Dawley rats weighing 125-150 grams were sacrificed by an intramuscular followed by a cardiac injection of catemine, submerged in ethanol, and transferred to a sterile culture hood for dissection. Following a mid-abdominal incision extending to the thorax, the ribs were resected to expose the thoracic cavity. The heart and lungs were moved aside to locate the thoracic aorta. The segment of the aorta distal to the aortic arch and extending to the diaphragm was removed and placed immediately in MCDB-131 medium containing 4 mM L-glutamine and 50 µg/ml gentamycin (buffer A). Buffer A was gently pipetted through the aorta with a pipetman to remove blood. The fibrous tissue was surrounding the aorta was carefully removed and the aorta was sliced into 1-2 mm sections with sterile razor blades. The sections were collected in 50 ml conical tubes and washed five times with fresh buffer A.

Twenty four-well culture plates were coated with 0.2 ml autoclaved 1.5% agarose in buffer A. After the agarose solidified, the wells were filled with 1 ml buffer A. One aortic segment was submerged in each well and incubated in a 35.5 °C/5% CO<sub>2</sub> humidified incubator for 10 days. Buffer A was replaced every 2 days. The aortic segments were collected in 50 ml conical tubes and washed five times with fresh buffer A.

One milliliter of autoclaved 1.5% agarose in buffer A was added to each well of a twenty four-well culture plate and allowed to solidify. Agarose wells were cut from the solidified agarose with ethanol-sterilized cork borers and placed in twelve-well culture plates. Collagen solution was prepared by mixing 12.8 ml Collaborative Biomedical Products rat tail type I collagen with 2 ml 7.5X Dulbecco's Modified Eagle's Medium adjusted to pH 7 with approximately 0.2 ml 1N NaOH. One hundred microliters of collagen solution was added to the base of the agarose wells and allowed to set in a 35.5 °C/5% CO<sub>2</sub> humidified incubator. Three hundred microliters of collagen solution supplemented with 0.5 nM bFGF and the desired concentration of test compound was added and an aortic segment was submerged within the upper collagen layer. Test compounds were initially dissolved in ethanol at a stock concentration of 0.1 mM, and subsequently diluted in buffer A and finally collagen solution to obtain concentrations from 0.1 nM to 100 nM. After the collagen set, the agarose wells were surrounded by 1.5 ml buffer A supplemented with 0.5 nM bFGF and the desired concentration of test angiogenesis inhibitor compound. The buffer surrounding the

wells was replaced every 48 hours. After seven days, the vessels protruding from the aortic rings were counted under a microscope.

The results of this assay, set forth herein in Figure 1, demonstrate that the angiogenesis inhibitor compounds of the invention have excellent angiogenesis

5 inhibitory activity (much better compared to the angiogenesis inhibitory activity of TNP-470).

### Example 28

The plasma stability of the angiogenesis inhibitor compounds of the invention  
10 was also tested in human plasma at 37°C (at a 20 µM concentration of the angiogenesis inhibitor compound). The matrix minus the test angiogenesis inhibitor compound was equilibrated at 37°C for 3 minutes. The assay was initiated by addition of the test compound, and the reaction mixture was incubated in a shaking water bath at 37°C. Aliquots (100µL) were withdrawn in triplicate at 0, 60, and 120 minutes and combined  
15 with 200µL of ice cold acetonitrile to terminate the reaction. The supernatant was analysed by Liquid Chromatography/Mass spectrometry (LC/MS) using a four point standard curve to obtain percent recovery.

The parent compound remaining (relative to time 0) in the incubation mixture was plotted as a function of time; a first order exponential equation was fit to the  
20 observed data, and the elimination half-lives associated with the disappearance of the test angiogenesis inhibitor compound were determined. Results are shown below in Table VI.

**Table VI**

Test Compound	Percent Recovery (Remaining)						T <sub>1/2</sub> (min)
	0 min	15 min	30 min	60 min	90 min	120 min	
5	100	108	103	97	129	107	≥500
20	110	114	114	120	106	103	≥500

25

The stability of the angiogenesis inhibitor compounds in liver microsomes was also tested. The test angiogenesis inhibitor compound at a concentration of 3µM was incubated with male rat liver microsomes (0.5 mg/mL protein) in the presence of a  
30 NADPH regenerating system (1 mM NADP, 10 mM G6P, 1 U/mL G6PDH2, 3 mM MgCl<sub>2</sub>) in 100mM Phosphate buffer at pH 7.4 at 37°C. Incubations were performed in the presence and absence of 1µM epoxide hydrolase (EH) inhibitor N-cyclohexyl-N'-(3-phenylpropyl) urea (M. Morisseau *et al.* (1999) *PNAS* 96:8849-54) and quantitative analysis performed using LC/MS/MS.

The parent compound remaining (relative to time 0) in the incubation mixture was plotted as a function of time; a first order exponential equation was fit to the observed data, and the elimination half-lives associated with the disappearance of the test compound were determined. Results are shown below in Table VII.

**Table VII**

Test Compound	T <sub>1/2</sub> (without EH inhibitor) mins	T <sub>1/2</sub> (with EH inhibitor) mins
TNP-470	> 1.0	> 1.0
5	11.9 ± 1	12.1 ± 1

**Example 29**

The efficacy of the compound described above in example 5 was evaluated using a collagen-induced arthritis model. Briefly, syngeneic 8-week-old female Louvain rats were immunized intradermally under ether anesthesia on Day 0 with 0.5 mg chick collagen II (Genzyme, Boston, MA) solubilized in 0.1M acetic acid and emulsified in Incomplete Freund's Adjuvant (Difco, Detroit, MI). Using this method, more than 90% of rats typically develop synovitis in both hind limbs 10-14 days post immunization. Rats demonstrating definite arthritis (47 total) were entered into the study and randomly assigned to one of four protocols. The compound of example 5 was dissolved in a combination of ethanol and distilled water. The rats were dosed commencing on day 10 post immunization as follows: (1) control group: vehicle only daily via intravenous injection (iv) (12 rats), (2) high dose group: 30 mg/kg of the compound of example 5 iv every other day (12 rats), (3) low dose group: 15 mg/kg of the compound of example 5 iv every day (12 rats) and (4) oral group: 100 mg/kg of the compound of example 5 every other day by gavage (11 rats).

Daily clinical evaluations of each paw were graded on an integer scale ranging from 0 to 4, where a score of 0 indicates a normal, unaffected limb, and 4 indicates severe joint destruction. The clinical score is the sum of the four limb scores, and has a maximum possible value of 16. Collagen induced arthritis typically develops only in the hind limbs; therefore, a score of 6 to 8 represents severe arthritis.

Radiologic evaluations of the hind limbs were performed by an investigator blinded to the treatment protocol. The score assigned to each limb was based on (1) the degree of soft tissue swelling, (2) narrowing of the space between joints, (3) degree of periosteal new bone formation and (4) the presence of erosions or ankylosis. Each limb was scored on a scale of 1 to 3, with 1 representing a normal limb and 3 representing severe joint destruction. Each rat, thus, had a maximum possible radiographic score of 6 (sum of both hind limbs).



The results of this study are set forth in Figure 2, which presents the mean daily clinical score for each of the four groups of rats over the 19 day period following induction of clinical arthritis (day 10). The results indicate that each treatment group received a significant therapeutic benefit from the compound of example 5. Consistent with these observations, the mean radiological evaluation scores were 2.2 for the control group, 0.6 for the high dose group, 0.6 for the low dose group and 1.6 for the oral group. Thus, each group treated with the compound of example 5 received a significant benefit with regard to joint destruction compared to the control group.

### Example 30

The compound of example 5 was also evaluated against a panel of cancer cell lines (Alley, M.C. *et al.* (1998) *Cancer Research* 48: 589-601; Grever, M.R., *et al.* (1992) *Seminars in Oncology*, Vol. 19, No. 6, pp 622-638; Boyd, M.R., and Paull, K.D. (1995) *Drug Development Research* 34: 91-109). The human tumor cell lines of the cancer screening panel were grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. Cells were inoculated into 96 well microtiter plates in 100  $\mu$ L at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the microtiter plates were incubated at 37° C, 5 % CO<sub>2</sub>, 95 % air and 100 % relative humidity for 24 hours prior to addition of experimental drugs.

After the 24 hour incubation period, two plates of each cell line were fixed *in situ* with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition (Tz). Experimental drugs were solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration and stored frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate was thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50  $\mu$ g/ml gentamicin. Additional four, 10-fold or ½ log serial dilutions were made to provide a total of five drug concentrations plus control. Aliquots of 100  $\mu$ l of these different drug dilutions were added to the appropriate microtiter wells already containing 100  $\mu$ l of medium, resulting in the required final drug concentrations.

Following drug addition, the plates were incubated for an additional 48 hours at 37°C, 5 % CO<sub>2</sub>, 95 % air, and 100 % relative humidity. For adherent cells, the assay was terminated by the addition of cold TCA. Cells were fixed *in situ* by the gentle addition of 50  $\mu$ l of cold 50 % (w/v) TCA (final concentration, 10 % TCA) and incubated for 60 minutes at 4°C. The supernatant was discarded, and the plates were washed five times with tap water and air dried. Sulforhodamine B (SRB) solution (100

μl) at 0.4 % (w/v) in 1 % acetic acid were added to each well, and plates were incubated for 10 minutes at room temperature. After staining, unbound dye was removed by washing five times with 1 % acetic acid and the plates were air dried. Bound stain was subsequently solubilized with 10 mM trizma base, and the absorbance was read on an automated plate reader at a wavelength of 515 nm. For suspension of the cells, the methodology used was the same except that the assay was terminated by fixing settled cells at the bottom of the wells by gently adding 50 μl of 80 % TCA (final concentration, 16 % TCA). Using the seven absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)], the percentage growth was calculated at each of the drug concentrations levels.

Percentage growth inhibition was calculated as:

$$[(Ti-Tz)/(C-Tz)] \times 100 \text{ for concentrations for which } Ti \geq Tz$$

$$[(Ti-Tz)/Tz] \times 100 \text{ for concentrations for which } Ti < Tz.$$

Growth inhibition of 50 % (GI<sub>50</sub>) was calculated from  $[(Ti-Tz)/(C-Tz)] \times 100 = 50$ , which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. The GI<sub>50</sub> was calculated for each of the cell lines if the level of activity is reached; however, if the effect was not reached or is exceeded, the value for that parameter is expressed as greater or less than the maximum (10<sup>-4</sup> M) or minimum (10<sup>-8</sup> M) concentration tested.

**Table VIII:** Effect of the compound of example 5 on tumor cell line panel

Cell line	Tumor type	GI <sub>50</sub> (moles liter <sup>-1</sup> )
HL-60(TB)	Leukemia	2.17 x 10 <sup>-5</sup>
K-562	Leukemia	6.44 x 10 <sup>-5</sup>
MOLT-4	Leukemia	3.56 x 10 <sup>-5</sup>
RPMI-8226	Leukemia	<1 x 10 <sup>-8</sup>
SR	Leukemia	<1 x 10 <sup>-8</sup>
EKVX	Non-Small Cell Lung	2.08 x 10 <sup>-5</sup>
HOP-62	Non-Small Cell Lung	<1 x 10 <sup>-8</sup>
HOP-92	Non-Small Cell Lung	3.39 x 10 <sup>-5</sup>
NCI-H226	Non-Small Cell Lung	7.91 x 10 <sup>-7</sup>
NCI-H23	Non-Small Cell Lung	6.34 x 10 <sup>-6</sup>
NCI-H322M	Non-Small Cell Lung	4.68 x 10 <sup>-8</sup>
NCI-H460	Non-Small Cell Lung	<1 x 10 <sup>-8</sup>
NCI-H522	Non-Small Cell Lung	1.29 x 10 <sup>-5</sup>

COLO 205	Colon	$<1 \times 10^{-8}$
HCT-116	Colon	$<1 \times 10^{-8}$
HCT-15	Colon	$7.13 \times 10^{-6}$
HT29	Colon	$1.61 \times 10^{-5}$
KM12	Colon	$<1 \times 10^{-8}$
SW-620	Colon	$>1 \times 10^{-4}$
SF-268	CNS	$2.61 \times 10^{-5}$
SF-295	CNS	$<1 \times 10^{-8}$
SF-539	CNS	$2.06 \times 10^{-5}$
SNB-19	CNS	$<1 \times 10^{-8}$
SNB-75	CNS	$9.09 \times 10^{-5}$
MALME-3M	Melanoma	$5.31 \times 10^{-8}$
M14	Melanoma	$<1 \times 10^{-8}$
SK-MEL-2	Melanoma	$>1 \times 10^{-4}$
SK-MEL-28	Melanoma	$5.96 \times 10^{-6}$
SK-MEL-5	Melanoma	$>1 \times 10^{-4}$
UACC-257	Melanoma	$1.48 \times 10^{-6}$
UACC-62	Melanoma	$<1 \times 10^{-8}$
IGR-OV1	Ovarian	$<1 \times 10^{-8}$
OVCAR-3	Ovarian	$4.18 \times 10^{-5}$
OVCAR-4	Ovarian	$3.66 \times 10^{-5}$
OVCAR-5	Ovarian	$1.35 \times 10^{-8}$
OVCAR-8	Ovarian	$1.84 \times 10^{-5}$
SK-OV-3	Ovarian	$7.37 \times 10^{-6}$
786-0	Renal	$1.61 \times 10^{-5}$
A498	Renal	$>1 \times 10^{-4}$
ACHN	Renal	$<1 \times 10^{-8}$
CAKI-1	Renal	$<1 \times 10^{-8}$
RXF 393	Renal	$4.02 \times 10^{-5}$
SN12C	Renal	$<1 \times 10^{-8}$
TK-10	Renal	$5.43 \times 10^{-8}$
PC-3	Prostate	$1.80 \times 10^{-5}$
DU-145	Prostate	$<1 \times 10^{-8}$
MCF7	Breast	$1.24 \times 10^{-5}$
NCI/ADR-RES	Breast	$3.42 \times 10^{-5}$
MDA-MB-231/ATCC	Breast	$<1 \times 10^{-8}$
HS 578T	Breast	$1.15 \times 10^{-6}$
MDA-N	Breast	$1.58 \times 10^{-6}$

### Results

- The results of the cell line screen, presented in Table VIII, show that the
- 5 compound of example 5 has a significant inhibitory effect on a wide variety of tumor cell lines. The results also show that certain cell lines are much more sensitive to the compound of example 5 than are others, indicating that this compound is selective for certain cell lines.

10

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
2211  
2212  
2213

**Equivalents**

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following

5 claims.